Invus Financial Advisors

Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, that specializes in developing small molecule therapies for severe, rare musculoskeletal diseases. Founded in 2017, the company employs a precision medicine approach to create innovative treatments targeting various muscle disorders, including Duchenne and Becker muscular dystrophies, as well as limb girdle muscular dystrophies. Utilizing its proprietary muscle-focused drug discovery platform, Edgewise integrates expertise in muscle biology and small molecule engineering to identify and develop therapies that address genetically defined muscle disorders. The company emphasizes a holistic drug discovery method that assesses integrated muscle function, enabling it to create orally bioavailable therapies aimed at improving outcomes for patients with significant unmet medical needs in neuromuscular and cardiac diseases.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

Ottimo Pharma specializes in developing innovative cancer therapies for solid tumors. Its primary focus is Jankistomig, a bi-functional antibody that targets both immune checkpoint inhibition and angiogenesis, two key pathways involved in cancer growth. By simultaneously addressing these pathways, Ottimo Pharma's approach offers healthcare professionals a dual-pronged strategy to potentially enhance treatment outcomes and reduce the burden of cancer on patients and the healthcare system.

Tasca is a biotechnology company that offers small molecule drugs for hard-to-treat oncology indications.

PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Seaport Therapeutics is a clinical stage biopharmaceutical company focused on developing innovative neuropsychiatric medicines for patients with significant unmet needs. The company's approach emphasizes the creation of treatments that offer oral bioavailability, which allows the medications to bypass first-pass metabolism. This method aims to reduce hepatotoxicity and other adverse side effects commonly associated with neuropsychiatric treatments. By addressing these critical issues, Seaport Therapeutics seeks to improve the quality of life for individuals living with neuropsychiatric disorders.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

City Therapeutics is a biopharmaceutical company specializing in the development of next-generation small-interfering RNAs (siRNAs) to enhance RNA interference (RNAi) therapies. The company's pipeline comprises innovative RNAi therapeutics targeting diverse disease indications. City Therapeutics aims to improve and expand RNAi technology to achieve better patient outcomes, led by a team of experienced scientists and industry professionals committed to advancing the field of RNA interference.

Egetis Therapeutics AB is a pharmaceutical drug development company based in Stockholm, Sweden, that specializes in late-stage projects targeting serious rare diseases with significant unmet medical needs, particularly within the orphan drug segment. The company is actively developing several innovative therapies, including PledOx, which is undergoing Phase III clinical trials to protect patients from chemotherapy-induced nerve damage while preserving the anticancer effects. Additionally, Egetis is working on Emcitate, a treatment for MCT8 deficiency, a rare genetic condition affecting thyroid hormone signaling, and Aladote, which aims to mitigate the risk of acute liver injury from acetaminophen poisoning. Founded in 2006, Egetis Therapeutics was previously known as PledPharma AB until its name change in December 2020.

Cartesian Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in the United States that specializes in developing innovative cell and gene immunotherapies for the treatment of cancer and autoimmune diseases. The company focuses on chimeric antigen receptor therapies to address multiple myeloma and other forms of cancer. Cartesian Therapeutics employs its proprietary ImmTOR immune tolerance platform, which aims to foster antigen-specific immunity while reducing unwanted immune responses. This approach utilizes a manufacturing platform to introduce mRNA molecules into cells, enhancing their functionality without the risk of integration into the cell's genetic material, as mRNA naturally degrades over time.

Alterome Therapeutics is a biotechnology company focused on precision oncology, dedicated to developing targeted therapeutics that specifically address validated oncogenic drivers in cancer. The firm aims to discover and create alteration-specific therapies that provide hope and improved treatment options for individuals affected by cancer. By concentrating on high-value oncogenic alterations, Alterome Therapeutics seeks to enhance the effectiveness of cancer treatments and support healthcare providers in their efforts to combat the disease.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products to treat various human diseases. The company's portfolio includes several drug candidates in different stages of clinical trials. LX9211 is an orally-delivered small molecule being tested for neuropathic pain treatment. Sotagliflozin, another orally-delivered small molecule, is under investigation for heart failure and type 1 diabetes. Additionally, the company has developed LX4211 for type 2 diabetes, LX2931 for rheumatoid arthritis and other autoimmune diseases, and LX7101 for glaucoma treatment. Lexicon Pharmaceuticals has established collaborations with several pharmaceutical companies, including Bristol-Myers Squibb, Genentech, Organon, Takeda, Symphony Icon, Taconic Farms, and Nuevolution A/S.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing nucleic acid therapeutics, particularly antisense oligonucleotides. Founded in 2018, the company aims to enhance the delivery and efficacy of these therapies through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative platform utilizes engineered peptides designed to improve tissue penetration, cellular uptake, and nuclear delivery of oligonucleotides. PepGen's technology has shown promise in preclinical studies, demonstrating the ability to transport therapeutics effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. The company's mission is to unlock the full potential of nucleic acid therapeutics to transform the treatment landscape for severe neuromuscular and neurological diseases.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

Health Data Analytics Institute, LLC specializes in developing an artificial intelligence-based analytics platform aimed at measuring clinical risks. Founded in 2016 and located in Dedham, Massachusetts, the institute utilizes electronic health record data and Blue Button data to provide real-time assessments and on-demand analytics regarding patient risks, including mortality, readmission, complications, and disease progression. The platform offers calibrated analytic models through the HDAI API, serving a diverse clientele that includes healthcare providers, researchers, administrators, and data scientists. By transforming complex health data into actionable insights, the institute aims to enhance patient care and support targeted treatment strategies across various healthcare settings.

Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, established in 2019, focused on developing adeno-associated virus (AAV)-based gene therapies for monogenic diseases affecting the central nervous system (CNS). The company’s product pipeline includes several therapies currently in development, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha Gene Therapies aims to translate innovative treatments from research to clinical practice efficiently, leveraging a strategic partnership with The University of Texas Southwestern Medical Center to enhance its development and commercialization capabilities. The company's mission is to create curative medicines that target both rare and prevalent CNS conditions, thereby addressing severe and life-threatening diseases.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.

Septerna is a biotechnology company focused on discovering and advancing novel small-molecule medicines that target G protein-coupled receptors (GPCRs). The company aims to improve patient outcomes by integrating innovative drug discovery technologies with GPCR drug targets. Utilizing its Native Complex platform, Septerna facilitates industrial-scale drug discovery through advanced screening technologies and structure-based drug design. This approach enables medical researchers to efficiently identify treatments for a variety of diseases.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

BelliWelli is a Los Angeles-based company that specializes in creating gut-friendly, plant-based snack bars designed for individuals with irritable bowel syndrome (IBS). Founded in 2020, the company offers four varieties of gluten-free, dairy-free, and low-sugar bars that are certified low-FODMAP. These products are formulated with ingredients such as almond butter, chia seeds, and cinnamon, aiming to enhance digestive health while providing a delicious snacking option. By focusing on the needs of those with IBS, BelliWelli seeks to raise awareness about gut health and promote suitable dietary choices.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Salt Lake City, Utah, that focuses on revolutionizing drug discovery through the integration of advanced technologies such as artificial intelligence, automation, and bioinformatics. Founded in 2013, the company has developed a comprehensive drug discovery platform that includes various tools and software, such as ReChem for chemical compound design, ReScreen for managing complex experimental workflows, and RePredict for modeling drug relationships using machine learning. These innovations enable Recursion to generate extensive biological and chemical datasets, facilitating the exploration of foundational biology and accelerating the development of new therapeutic solutions. Through its unique approach, Recursion aims to significantly enhance patient outcomes and streamline the drug discovery process.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

Sironax is a clinical-stage biotechnology company based in Beijing, China, founded in 2017. The company focuses on developing innovative products and treatments for age-related degenerative diseases, concentrating on mechanisms such as regulated cell death, neuroprotective pathways, and neuroinflammation. By researching apoptosis and other cell death pathways, Sironax aims to create advanced pharmaceuticals that can improve the lives of patients suffering from these conditions. Their goal is to transform the treatment landscape for age-related degenerative diseases, benefiting millions of patients and their families globally.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products to treat various human diseases. The company's portfolio includes several drug candidates in different stages of clinical trials. LX9211 is an orally-delivered small molecule being tested for neuropathic pain treatment. Sotagliflozin, another orally-delivered small molecule, is under investigation for heart failure and type 1 diabetes. Additionally, the company has developed LX4211 for type 2 diabetes, LX2931 for rheumatoid arthritis and other autoimmune diseases, and LX7101 for glaucoma treatment. Lexicon Pharmaceuticals has established collaborations with several pharmaceutical companies, including Bristol-Myers Squibb, Genentech, Organon, Takeda, Symphony Icon, Taconic Farms, and Nuevolution A/S.

Vascular Dynamics, Inc. is a privately-held medical technology company founded in 2008 and based in Irvine, California. The company specializes in developing catheter-delivered implants for the treatment of drug-resistant hypertension. Its primary product, MobiusHD, utilizes a minimally invasive procedure to enhance the body's natural baroreceptor response in the carotid sinus, promoting vasodilation, lowering heart rate, modulating kidney response, and ultimately reducing blood pressure. Vascular Dynamics aims to provide effective treatment options for patients at risk of severe health conditions associated with high blood pressure, such as heart disease, stroke, and kidney disease. The team at Vascular Dynamics has over 75 years of combined experience in medical device development and commercialization.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, an off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A, a treatment for hepatocellular carcinoma.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

Septerna is a biotechnology company focused on discovering and advancing novel small-molecule medicines that target G protein-coupled receptors (GPCRs). The company aims to improve patient outcomes by integrating innovative drug discovery technologies with GPCR drug targets. Utilizing its Native Complex platform, Septerna facilitates industrial-scale drug discovery through advanced screening technologies and structure-based drug design. This approach enables medical researchers to efficiently identify treatments for a variety of diseases.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Abata Therapeutics is dedicated to developing innovative cell therapies aimed at treating autoimmune and inflammatory diseases, particularly progressive multiple sclerosis and type 1 diabetes. The company focuses on harnessing regulatory T cells (Tregs) to restore balance in the immune system, engineering these cells to specifically target disease-related antigens for precise treatment. This approach allows for effective disease management without the need for systemic immune suppression, enabling patients to maintain stable and active tissue residency. Founded by experts in immunology and cell therapy, Abata has garnered substantial investment from venture capital and biopharmaceutical firms, with the mission of translating advanced scientific research into meaningful therapies that enhance the quality of life for individuals affected by chronic autoimmune conditions.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

Escale is a digital marketing agency based in Sao Paulo, Brazil, founded by Matthew Kligerman and Ken Diamond in 2013. The company specializes in customer acquisition services, primarily serving enterprises in the telecommunications and healthcare sectors across Brazil. Escale's platform manages the entire marketing and sales funnel, from online demand generation to lead management, conversion, and customer onboarding. The company operates on a commission model, aligning its performance with that of its clients. By leveraging data and technology, Escale transforms web and cloud voice interactions into actionable data points, enhancing return on investment for its customers.

Repertoire Immune Medicines is a clinical-stage biotechnology company founded in 2016 and based in Cambridge, Massachusetts. The company focuses on harnessing the power of T cells to develop innovative therapies aimed at preventing, treating, and curing cancer, autoimmune conditions, and infectious diseases. Repertoire Immune Medicines is actively engaged in experimental clinical trials that utilize autologous T cells primed against specific cancer antigens and linked to IL-15. Additionally, the company specializes in the characterization of T cell receptor (TCR)-antigen pairs, allowing for the rational design and development of targeted immune medicines. These efforts are designed to enhance the human immune system's capabilities, providing new treatment options for patients with serious health challenges.

Omega Therapeutics is a development-stage biotechnology company based in Cambridge, Massachusetts, focused on developing genomic medicines aimed at curing diseases. The company utilizes its proprietary epigenomic programming platform to create a new class of programmable epigenetic medicines, referred to as Omega Epigenomic Controllers. These controllers are designed to selectively modulate genomic activity, enabling precise tuning of the human genome to treat various medical conditions. Founded in 2016 and rebranded from VL42, Inc. in 2017, Omega Therapeutics is dedicated to transforming human medicine by harnessing the innate potential of the genome for therapeutic benefits.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, founded in 2017. It focuses on developing cell and gene therapies for the treatment of cancer and viral infections. The company operates a portfolio of subsidiaries that aim to manufacture and commercialize innovative medicines. ElevateBio collaborates with leading scientists and inventors to create a robust portfolio of therapeutic solutions. Additionally, it has established a centralized facility designed to streamline the translation of cell and gene therapy research into viable medical products, ensuring that patients have access to treatments for severe diseases in a timely manner.

Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, founded in 2016. The company specializes in developing exosome-based therapeutics aimed at treating rare and severe diseases. By harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, Evox focuses on creating innovative drug delivery systems that utilize nucleic acids and proteins. This technology allows for targeted delivery to specific organs, including the brain and central nervous system, addressing limitations often encountered with traditional therapies. Evox's proprietary methods for modifying exosomes enhance their ability to transport therapeutic agents effectively, thereby improving treatment options for patients with limited alternatives. The company is supported by a strong intellectual property portfolio and investments from leading life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based therapeutics.

Sagimet Biosciences is a clinical-stage biopharmaceutical company based in San Mateo, California, that specializes in developing novel therapeutics for oncology and infectious diseases. The company focuses on targeting dysfunctional metabolic pathways, particularly through its expertise in fatty acid synthase (FASN) biology. Its lead drug candidate, denifanstat, is a selective FASN inhibitor designed for the treatment of nonalcoholic steatohepatitis (NASH) and is administered as an oral, once-daily pill. Additionally, Sagimet is working on antiviral therapeutics aimed at addressing respiratory syncytial virus, cytomegalovirus, and other human pathogens. Originally known as 3-V Biosciences, Inc., the company rebranded to Sagimet Biosciences in August 2019 and has been active since its incorporation in 2006.

Valo Health, Inc (Valo) is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York, NY. To learn more, visit valohealth.com.

Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.

Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

Faze Medicines is a biotechnology company founded in 2020 and located in Cambridge, Massachusetts. The company focuses on developing small molecule drugs that target the underlying mechanisms of disease pathology, with initial therapeutic efforts directed towards conditions such as amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). Faze Medicines employs advanced screening and proteomics techniques to explore biomolecular condensate interaction networks, which aids in the identification and development of novel therapeutics. Through its innovative approach, Faze aims to provide effective treatments for patients suffering from these challenging diseases.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, that specializes in the development of engineered precision biologics using an advanced genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, leading to the creation of next-generation therapeutics, including antibody drug conjugates (ADCs), bispecific antibodies, and long-acting therapeutic peptides. Ambrx's development pipeline features several product candidates, such as ARX788, ARX517, and ARX305, which target various therapeutic areas, including oncology, metabolic, and cardiovascular diseases. The company collaborates with organizations like MabSpace Biosciences, BeiGene, and NovoCodex Biopharmaceuticals to enhance its research and development efforts. Founded in 2003, Ambrx aims to optimize the efficacy, safety, and usability of its biopharmaceutical products.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

TigerConnect is a provider of clinical communication solutions tailored for the healthcare sector, enabling effective collaboration among doctors, nurses, patients, and care providers. Founded in 2010 and headquartered in Santa Monica, California, the company offers a platform that integrates real-time mobile messaging with a user-friendly interface, while prioritizing security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. Its innovative products and seamless integrations with essential hospital systems enhance workflow efficiency, ultimately accelerating productivity, reducing costs, and improving patient outcomes. The company's commitment to client success is evident through its dedicated support organization, which collaborates with clients to optimize communication workflows and maximize return on investment.

PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and headquartered in San Mateo, California, the company focuses on targeting dysregulated transcription factors and oncogenic signaling pathways. Its lead candidate, entospletinib, is a selective inhibitor of spleen tyrosine kinase aimed at treating acute myeloid leukemia. Additionally, Kronos Bio is developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9, intended for MYC-amplified solid tumors. By leveraging advanced technologies such as high-throughput small-molecule microarrays and targeted protein degradation, Kronos Bio aims to identify effective compounds that can modulate historically undruggable cancer targets, ultimately striving to improve patient outcomes through precision medicine.

Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, established in 2019, focused on developing adeno-associated virus (AAV)-based gene therapies for monogenic diseases affecting the central nervous system (CNS). The company’s product pipeline includes several therapies currently in development, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha Gene Therapies aims to translate innovative treatments from research to clinical practice efficiently, leveraging a strategic partnership with The University of Texas Southwestern Medical Center to enhance its development and commercialization capabilities. The company's mission is to create curative medicines that target both rare and prevalent CNS conditions, thereby addressing severe and life-threatening diseases.

Thrive Earlier Detection Corp. is a healthcare company that specializes in developing advanced blood testing technologies for early cancer detection. Its flagship product, CancerSEEK, is a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma, allowing for the identification of various cancers at their nascent stages, often before symptoms manifest. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate cancer screening into standard medical practice. The company leverages real-world data and machine learning to enhance the accuracy of cancer detection, facilitate follow-up testing, and streamline the transition to oncological care. Thrive operates as a subsidiary of Exact Sciences Corporation and has received investments from notable firms including Third Rock Ventures and Section 32.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

Imvax, Inc. is a clinical-stage biotechnology company based in Philadelphia, Pennsylvania, focused on developing patient-specific vaccines and immunotherapy strategies for treating malignant gliomas and other cancers. Founded in 2015, Imvax's key product, IGV-001, is an autologous tumor cell vaccine designed to harness the patient’s immune system to mount a comprehensive attack on tumor cells. The company employs advanced methodologies, including patient cell harvesting, treatment and implantation, as well as strategies that promote immunogenic cell death and activate both the innate and adaptive immune responses. By addressing unmet medical needs in cancer therapy, Imvax aims to provide innovative treatment options for patients suffering from challenging malignancies.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.

iTeos Therapeutics is a biopharmaceutical company dedicated to developing immuno-oncology therapies for cancer patients. Founded in 2011, the company operates from headquarters in Cambridge, Massachusetts, and Gosselies, Belgium. iTeos focuses on discovering and advancing small molecule immunomodulators that target the tumor microenvironment, aiming to enhance the body's immune response against cancer. Its pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor, and EOS-448, an antagonist of TIGIT, both currently in Phase 1/2a clinical trials. iTeos' approach is built on the expertise of Ludwig Cancer Research, aiming to improve clinical outcomes by restoring the immune system's ability to fight cancer.

ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, founded in 2017. It focuses on developing cell and gene therapies for the treatment of cancer and viral infections. The company operates a portfolio of subsidiaries that aim to manufacture and commercialize innovative medicines. ElevateBio collaborates with leading scientists and inventors to create a robust portfolio of therapeutic solutions. Additionally, it has established a centralized facility designed to streamline the translation of cell and gene therapy research into viable medical products, ensuring that patients have access to treatments for severe diseases in a timely manner.

Health Data Analytics Institute, LLC specializes in developing an artificial intelligence-based analytics platform aimed at measuring clinical risks. Founded in 2016 and located in Dedham, Massachusetts, the institute utilizes electronic health record data and Blue Button data to provide real-time assessments and on-demand analytics regarding patient risks, including mortality, readmission, complications, and disease progression. The platform offers calibrated analytic models through the HDAI API, serving a diverse clientele that includes healthcare providers, researchers, administrators, and data scientists. By transforming complex health data into actionable insights, the institute aims to enhance patient care and support targeted treatment strategies across various healthcare settings.

Element Science, Inc. is a medical device and digital health company focused on developing solutions for high-risk cardiovascular patients. The company's flagship product is a patch-based wearable cardioverter defibrillator that continuously monitors heart activity to protect against sudden cardiac death. This device integrates advanced data science and machine learning algorithms with strict electromechanical medical device standards, creating a proprietary digital platform that enhances patient care as individuals transition from hospital to home. Founded in 2011 and headquartered in San Francisco, California, Element Science aims to address critical health needs and reduce hospitalization rates associated with heart disease. The company was previously known as Revive Defibrillation Systems, Inc. before adopting its current name in 2014.

Viseon, Inc. is a medical device company based in Irvine, California, focused on developing innovative technologies for Minimally Invasive Spine Surgery (MISS). Established in 2017 as a spin-out from Rebound Therapeutics Corporation, Viseon has created the Voyant technology, which serves as a single-use disposable alternative to traditional surgical microscopes, endoscopes, and loupes. This technology enhances surgical procedures by projecting the operative field onto a high-definition flat panel display, accessible both in the operating room and remotely. Viseon has rapidly advanced its product development, building a portfolio of devices aimed at improving clinical outcomes in spine surgery. The company holds 13 patents to protect its intellectual property and has formed a Scientific Advisory Board comprised of leading physicians in the field. Initial human-use studies are scheduled to commence soon, following successful pre-clinical trials.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

Triplet Therapeutics, Inc. is focused on developing innovative therapies for repeat expansion disorders, which include conditions such as Huntington’s disease, myotonic dystrophy, and spinocerebellar ataxias. Founded in 2018 and based in Cambridge, Massachusetts, the company aims to address these disorders at their source by utilizing a unique approach that involves targeting the DNA Damage Response pathway through a single oligonucleotide. This biotherapeutic technology is designed to provide a comprehensive treatment solution for multiple repeat expansion disorders, enabling healthcare professionals to better manage these complex conditions.

Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.

Thrive Market, Inc. is a membership-based online shopping platform founded in 2014 and based in Culver City, California. The company aims to make healthy living accessible and affordable by providing a wide range of high-quality, organic, and non-GMO products at wholesale prices. Thrive Market offers over 5,000 items across various categories, including food, health, beauty, home, and pet supplies, allowing customers to shop according to their dietary preferences and lifestyles. The platform serves both residential and commercial customers throughout the United States. In addition to its core mission, Thrive Market matches every paid membership with a free membership for someone in need, and has initiated programs like Thrive Gives, which raises funds to support food access and environmental sustainability initiatives.

Inotrem S.A. is a biotechnology company that specializes in immunotherapy aimed at managing acute and chronic inflammatory syndromes. The company focuses on the TREM-1 pathway to regulate excessive inflammatory responses, utilizing its proprietary technology platform. Inotrem has developed a first-in-class TREM-1 inhibitor known as nangibotide (LR12), which shows promise in treating conditions such as septic shock and myocardial infarction. In addition to its acute inflammatory initiatives, Inotrem is also advancing a program targeting chronic inflammatory diseases, thereby expanding its therapeutic scope. Through its innovative approach, Inotrem aims to enhance treatment options for critical care patients facing a variety of inflammatory challenges.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatments. Founded in 2014 and based in South San Francisco, the company’s lead product candidate, ORIC-101, is a small molecule antagonist of the glucocorticoid receptor, which is associated with resistance to various cancer therapies in solid tumors. Its second candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, targeting a critical component of the adenosine pathway linked to resistance against chemotherapy and immunotherapy. In addition to these products, ORIC is advancing multiple precision medicines aimed at addressing other mechanisms of cancer resistance. The company’s founders, Charles Sawyers and Scott Lowe, have extensive experience in identifying novel cancer targets that have led to innovative therapies.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and headquartered in San Mateo, California, the company focuses on targeting dysregulated transcription factors and oncogenic signaling pathways. Its lead candidate, entospletinib, is a selective inhibitor of spleen tyrosine kinase aimed at treating acute myeloid leukemia. Additionally, Kronos Bio is developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9, intended for MYC-amplified solid tumors. By leveraging advanced technologies such as high-throughput small-molecule microarrays and targeted protein degradation, Kronos Bio aims to identify effective compounds that can modulate historically undruggable cancer targets, ultimately striving to improve patient outcomes through precision medicine.

BioNTech is a Germany-based biotechnology company that specializes in developing innovative immunotherapies for cancer and other serious diseases, as well as vaccines for infectious diseases, including COVID-19. The company’s oncology pipeline includes a range of drug classes, such as mRNA-based drugs that encode antigens and neoantigens, cell therapies, bispecific antibodies, and antibody-drug conjugates. BioNTech has established partnerships with several major pharmaceutical companies, enhancing its research and development capabilities. Its COVID-19 vaccine, Comirnaty, represents its first commercialized product, demonstrating the company's commitment to addressing urgent health challenges through advanced therapeutic approaches.

Thrive Earlier Detection Corp. is a healthcare company that specializes in developing advanced blood testing technologies for early cancer detection. Its flagship product, CancerSEEK, is a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma, allowing for the identification of various cancers at their nascent stages, often before symptoms manifest. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate cancer screening into standard medical practice. The company leverages real-world data and machine learning to enhance the accuracy of cancer detection, facilitate follow-up testing, and streamline the transition to oncological care. Thrive operates as a subsidiary of Exact Sciences Corporation and has received investments from notable firms including Third Rock Ventures and Section 32.

Escale is a digital marketing agency based in Sao Paulo, Brazil, founded by Matthew Kligerman and Ken Diamond in 2013. The company specializes in customer acquisition services, primarily serving enterprises in the telecommunications and healthcare sectors across Brazil. Escale's platform manages the entire marketing and sales funnel, from online demand generation to lead management, conversion, and customer onboarding. The company operates on a commission model, aligning its performance with that of its clients. By leveraging data and technology, Escale transforms web and cloud voice interactions into actionable data points, enhancing return on investment for its customers.

Hookipa Pharma Inc. is a clinical stage biopharmaceutical company focused on developing innovative immunotherapeutics for infectious diseases and cancers through its proprietary arenavirus platform. The company employs its advanced Vaxwave and TheraT technologies to stimulate robust immune responses, generating antigen-specific killer T cells and antibodies. Hookipa's lead candidate for infectious diseases, HB-101, is currently undergoing a Phase II clinical trial targeting patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, its product candidates HB-201 and HB-202 are in preclinical studies aimed at treating human papillomavirus-positive cancers. Additionally, Hookipa collaborates with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011, the company is headquartered in New York, New York.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.

Kaleido Biosciences is a clinical-stage healthcare company that focuses on harnessing the potential of the microbiome to treat diseases and enhance human health. The company has developed a proprietary product platform that enables the efficient discovery and development of Microbiome Metabolic Therapies (MMTs). These therapies aim to modify the metabolic output and profile of the microbiome by influencing the function and distribution of its existing microbes. Kaleido is advancing a diverse pipeline of MMT candidates targeting various diseases and conditions that address significant unmet patient needs.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.

PACT Pharma, Inc. is a biotechnology company focused on developing personalized cell-based therapies for cancer treatment, specifically through neoantigen-specific adoptive T-cell therapies aimed at solid tumors. The company utilizes bioinformatics to analyze the DNA and RNA of patients' tumors and normal tissues, identifying candidate neoantigen peptides that can stimulate targeted antitumor T-cell responses. By recognizing unique neo-epitopes associated with individual cancers, PACT Pharma enables the engineering of autologous T cells designed to specifically target and eliminate tumor cells expressing these neoantigens. Founded in 2016 and based in South San Francisco, California, PACT Pharma is dedicated to advancing innovative treatment options for patients with cancer.